Barrington Research maintains Haemonetics at Outperform, raises price target to $145 from $140
Barrington Research maintained its Outperform rating on Haemonetics and raised its price target to $145 from $140, implying a 16.8% upside from the Nov 5 close of $124.11. Recent analyst price targets for Haemonetics range from $140 to $142.
How this was made
The 30-second read
Why it matters
The upgrade signals confidence in Haemonetics' growth trajectory, likely prompting short-term buying.
Market read
Analyst target increase provides a fresh data point for traders evaluating Haemonetics.
What to watch
Potential regulatory or reimbursement changes could offset the upside.
Background
Analyst price target adjustments are common catalysts for short-term price moves.
Ticker impact
Barrington Research raised Haemonetics' price target to $145 from $140, indicating a bullish outlook.
potential upward pressure as investors price in the higher target
The new target suggests improved expectations for earnings and growth, prompting traders to consider long positions.
Market effects
May lift sentiment in the medical devices sector.
Limited to U.S. markets where Haemonetics trades.
Minimal global impact beyond sector peers.
Counterpoint
The target raise could be premature if upcoming earnings miss expectations.
Key entities
- analystBarrington Research
Equity research firm that issued the price target raise.
